par Brom, Maarten;Woliner-van der Weg, Wietske;Joosten, Lieke;Frielink, Cathelijne;Bouckenooghe, Thomas 
;Rijken, Paul;Andralojc, Karolina;Göke, Burkhard J;de Jong, Marion;Eizirik, Decio L. ;Béhé, Martin;Lahoutte, Tony;Oyen, Wim J G;Tack, Cees J;Janssen, Marcel;Boerman, Otto C;Gotthardt, Martin
Référence Diabetologia, 57, 5, page (950-959)
Publication Publié, 2014
;Rijken, Paul;Andralojc, Karolina;Göke, Burkhard J;de Jong, Marion;Eizirik, Decio L. ;Béhé, Martin;Lahoutte, Tony;Oyen, Wim J G;Tack, Cees J;Janssen, Marcel;Boerman, Otto C;Gotthardt, MartinRéférence Diabetologia, 57, 5, page (950-959)
Publication Publié, 2014
Article révisé par les pairs
| Résumé : | A reliable method for in vivo quantification of pancreatic beta cell mass (BCM) could lead to further insight into the pathophysiology of diabetes. The glucagon-like peptide 1 receptor, abundantly expressed on beta cells, may be a suitable target for imaging. We investigated the potential of radiotracer imaging with the GLP-1 analogue exendin labelled with indium-111 for determination of BCM in vivo in a rodent model of beta cell loss and in patients with type 1 diabetes and healthy individuals. |
